Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. (Q51750364)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Dan Su

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Peter Schwartz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Thomas J Rutherford

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Saverio Danese

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Shenglin Ma

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Herbert Yu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Dionyssios Katsaros

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

English

0 references

publication date

1 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

2453-2463

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19322891%20AND%20SRC:MED&resulttype=core&format=json

Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells

24 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

Systemic therapy for ovarian cancer: current status and new treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Platinum resistance: the role of DNA repair pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

A synergistic relationship between three regions of stathmin family proteins is required for the formation of a stable complex with tubulin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Response rate as an endpoint in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Response rates, survival, and chemotherapy trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Stathmin: A Tubulin-Sequestering Protein Which Forms a Ternary T2S Complex with Two Tubulin Molecules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Expression of stathmin, a microtubule regulatory protein, is associated with the migration and differentiation of cultured early trophoblasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24282

7 January 2021